{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,25]],"date-time":"2026-10-25T21:32:32Z","timestamp":1792963952504,"version":"4.5.0"},"reference-count":68,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2023,2,1]],"date-time":"2023-02-01T00:00:00Z","timestamp":1675209600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2023,2,1]],"date-time":"2023-02-01T00:00:00Z","timestamp":1675209600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2023,1,5]],"date-time":"2023-01-05T00:00:00Z","timestamp":1672876800000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"DOI":"10.13039\/100004334","name":"Merck","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004334","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100009947","name":"Merck Sharp and Dohme","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100009947","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","lungcancerjournal.info","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Lung Cancer"],"published-print":{"date-parts":[[2023,2]]},"DOI":"10.1016\/j.lungcan.2023.01.003","type":"journal-article","created":{"date-parts":[[2023,1,2]],"date-time":"2023-01-02T18:57:55Z","timestamp":1672685875000},"page":"132-139","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":11,"special_numbering":"C","title":["Efficacy and safety of treatments for advanced thymic carcinoma after failure of first-line platinum-based chemotherapy: A systematic literature review and meta-analysis"],"prefix":"10.1016","volume":"176","author":[{"given":"Ashwini","family":"Arunachalam","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ina","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bin","family":"Zhao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andrew M.","family":"Frederickson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"M.","family":"Catherine Pietanza","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"11","key":"10.1016\/j.lungcan.2023.01.003_b0005","doi-asserted-by":"crossref","first-page":"2727","DOI":"10.1002\/1097-0142(19871201)60:11<2727::AID-CNCR2820601125>3.0.CO;2-D","article-title":"Thymoma. A clinicopathologic review","volume":"60","author":"Lewis","year":"1987","journal-title":"Cancer"},{"issue":"1","key":"10.1016\/j.lungcan.2023.01.003_b0010","doi-asserted-by":"crossref","first-page":"4","DOI":"10.1016\/j.lungcan.2008.01.014","article-title":"A review of thymic tumours","volume":"60","author":"Srirajaskanthan","year":"2008","journal-title":"Lung Cancer (Amsterdam, Netherlands)"},{"issue":"5","key":"10.1016\/j.lungcan.2023.01.003_b0015","doi-asserted-by":"crossref","first-page":"1550","DOI":"10.1016\/S0003-4975(00)01140-1","article-title":"Prognostic relevance of Masaoka and M\u00fcller-Hermelink classification in patients with thymic tumors","volume":"69","author":"Lardinois","year":"2000","journal-title":"Ann. Thorac. Surg."},{"issue":"2","key":"10.1016\/j.lungcan.2023.01.003_b0020","doi-asserted-by":"crossref","first-page":"307","DOI":"10.1016\/S1010-7940(01)01091-0","article-title":"Prognostic factors in thymic epithelial neoplasms","volume":"21","author":"R\u00edos","year":"2002","journal-title":"Eur. J. Cardiothorac. Surg."},{"issue":"12","key":"10.1016\/j.lungcan.2023.01.003_b0025","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0227197","article-title":"Trends in the incidence of thymoma, thymic carcinoma, and thymic neuroendocrine tumor in the United States","volume":"14","author":"Hsu","year":"2019","journal-title":"PLoS One"},{"key":"10.1016\/j.lungcan.2023.01.003_b0030","doi-asserted-by":"crossref","unstructured":"U. Ahmad, X. Yao, F. Detterbeck, J. Huang, A. Antonicelli, P.L. Filosso, E. Ruffini, W. Travis, D.R. Jones, Y. Zhan, Thymic carcinoma outcomes and prognosis: results of an international analysis, J. Thorac. Cardiovasc. Surg. 149(1) (2015) 95-101. e2.","DOI":"10.1016\/j.jtcvs.2014.09.124"},{"issue":"12","key":"10.1016\/j.lungcan.2023.01.003_b0035","doi-asserted-by":"crossref","first-page":"1810","DOI":"10.1097\/JTO.0000000000000363","article-title":"Clinical characteristics and outcomes for patients with thymic carcinoma: evaluation of Masaoka staging","volume":"9","author":"Litvak","year":"2014","journal-title":"J. Thorac. Oncol."},{"issue":"3","key":"10.1016\/j.lungcan.2023.01.003_b0040","doi-asserted-by":"crossref","first-page":"878","DOI":"10.1016\/S0003-4975(03)00555-1","article-title":"Therapy for thymic epithelial tumors: a clinical study of 1,320 patients from Japan","volume":"76","author":"Kondo","year":"2003","journal-title":"Ann. Thorac. Surg."},{"issue":"4","key":"10.1016\/j.lungcan.2023.01.003_b0045","doi-asserted-by":"crossref","first-page":"136","DOI":"10.1016\/j.fjs.2011.08.007","article-title":"Thymic carcinoma: A rare cancer requiring special attention","volume":"44","author":"Tseng","year":"2011","journal-title":"Formosan J. Surg."},{"issue":"12","key":"10.1016\/j.lungcan.2023.01.003_b0050","doi-asserted-by":"crossref","first-page":"775","DOI":"10.6061\/clinics\/2015(12)03","article-title":"Chemotherapy and prognosis in advanced thymic carcinoma patients","volume":"70","author":"Song","year":"2015","journal-title":"Clinics"},{"key":"10.1016\/j.lungcan.2023.01.003_b0055","unstructured":"National Comprehensive Cancer Network, Thymomas and Thymic Carcinomas (V1.2022), 2022. https:\/\/www.nccn.org\/professionals\/physician_gls\/pdf\/thymic.pdf."},{"key":"10.1016\/j.lungcan.2023.01.003_b0060","doi-asserted-by":"crossref","unstructured":"P.J.W. Loehrer Sr, W.;Johnson, D. H.;Ettinger, D. S., Octreotide alone or with prednisone in patients with advanced thymoma and thymic carcinoma: An Eastern Cooperative Oncology Group phase II trial, J. Clin. Oncol. 22(2) (2004) 293-299doi: 10.1200\/JCO.2004.02.047.","DOI":"10.1200\/JCO.2004.02.047"},{"issue":"12) (no pagination)(e0168215","key":"10.1016\/j.lungcan.2023.01.003_b0065","article-title":"Octreotide LAR and prednisone as neoadjuvant treatment in patients with primary or locally recurrent unresectable thymic tumors: A phase II study","volume":"11","author":"Kirzinger","year":"2016","journal-title":"PLoS One"},{"key":"10.1016\/j.lungcan.2023.01.003_b0070","doi-asserted-by":"crossref","first-page":"v40","DOI":"10.1093\/annonc\/mdv277","article-title":"Thymic epithelial tumours: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up","volume":"26","author":"Girard","year":"2015","journal-title":"Ann. Oncol."},{"issue":"2","key":"10.1016\/j.lungcan.2023.01.003_b0075","doi-asserted-by":"crossref","first-page":"323","DOI":"10.1007\/s00432-014-1800-6","article-title":"Key components of chemotherapy for thymic malignancies: a systematic review and pooled analysis for anthracycline-, carboplatin-or cisplatin-based chemotherapy","volume":"141","author":"Okuma","year":"2015","journal-title":"J. Cancer Res. Clin. Oncol."},{"issue":"4","key":"10.1016\/j.lungcan.2023.01.003_b0080","doi-asserted-by":"crossref","first-page":"495","DOI":"10.1016\/j.ctrv.2013.11.003","article-title":"Thymic neoplasms: an update on the use of chemotherapy and new targeted therapies. A literature review","volume":"40","author":"Berardi","year":"2014","journal-title":"Cancer Treat. Rev."},{"issue":"1","key":"10.1016\/j.lungcan.2023.01.003_b0085","doi-asserted-by":"crossref","first-page":"115","DOI":"10.1016\/j.jtho.2015.09.007","article-title":"Are anthracycline-based regimens truly indicated to be the standard chemotherapy regimen for thymic carcinoma?","volume":"11","author":"Hirai","year":"2016","journal-title":"J. Thorac. Oncol."},{"key":"10.1016\/j.lungcan.2023.01.003_b0090","doi-asserted-by":"crossref","first-page":"25","DOI":"10.1016\/j.lungcan.2018.10.018","article-title":"Systemic treatments for thymoma and thymic carcinoma: a systematic review","volume":"126","author":"Berghmans","year":"2018","journal-title":"Lung Cancer (Amsterdam, Netherlands)"},{"issue":"10","key":"10.1016\/j.lungcan.2023.01.003_b0095","doi-asserted-by":"crossref","first-page":"1006","DOI":"10.1016\/j.jclinepi.2009.06.005","article-title":"Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement","volume":"62","author":"D. Moher, A. Liberati, J. Tetzlaff, D.G. Altman, P. Group","year":"2009","journal-title":"J. Clin. Epidemiol."},{"key":"10.1016\/j.lungcan.2023.01.003_b0100","unstructured":"G.S. Wells, D. O'Connell, J. Peterson, V. Welch, M. Losos, The Newcastle-Ottawa Scale (NOS) for assessing the quality of nonrandomised studies in meta-analyses, 2013. http:\/\/www.ohri.ca\/programs\/clinical_epidemiology\/oxford.asp. (Accessed October 1 2016)."},{"key":"10.1016\/j.lungcan.2023.01.003_b0105","doi-asserted-by":"crossref","first-page":"404","DOI":"10.1093\/biomet\/26.4.404","article-title":"The use of confidence or fiducial limits illustrated in the case of the binomial","author":"Clopper","year":"1934","journal-title":"Biometrika"},{"key":"10.1016\/j.lungcan.2023.01.003_b0110","unstructured":"J.C. Paezzullo, Exact Binomial and Poisson Confidence Intervals, 2009. https:\/\/statpages.info\/confint.html."},{"issue":"4","key":"10.1016\/j.lungcan.2023.01.003_b0115","doi-asserted-by":"crossref","first-page":"153","DOI":"10.1136\/ebmental-2019-300117","article-title":"How to perform a meta-analysis with R: a practical tutorial","volume":"22","author":"Balduzzi","year":"2019","journal-title":"Evid. Based Ment. Health"},{"key":"10.1016\/j.lungcan.2023.01.003_b0120","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1186\/1471-2288-12-9","article-title":"Enhanced secondary analysis of survival data: reconstructing the data from published Kaplan-Meier survival curves","volume":"12","author":"Guyot","year":"2012","journal-title":"BMC Med. Res. Methodol."},{"issue":"3\u20134","key":"10.1016\/j.lungcan.2023.01.003_b0125","doi-asserted-by":"crossref","first-page":"258","DOI":"10.1002\/jrsm.25","article-title":"Network meta-analysis of parametric survival curves","volume":"1","author":"Ouwens","year":"2010","journal-title":"Res. Synth. Methods"},{"issue":"1","key":"10.1016\/j.lungcan.2023.01.003_b0130","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1186\/1471-2288-11-61","article-title":"Network meta-analysis of survival data with fractional polynomials","volume":"11","author":"Jansen","year":"2011","journal-title":"BMC Med. Res. Methodol."},{"issue":"4","key":"10.1016\/j.lungcan.2023.01.003_b0135","doi-asserted-by":"crossref","first-page":"583","DOI":"10.1111\/1467-9868.00353","article-title":"Bayesian measures of model complexity and fit","volume":"64","author":"Spiegelhalter","year":"2002","journal-title":"J. R. Stat. Soc. Ser. B (Stat Methodol.)"},{"issue":"3","key":"10.1016\/j.lungcan.2023.01.003_b0140","doi-asserted-by":"crossref","first-page":"1096","DOI":"10.1007\/s10637-011-9666-9","article-title":"A phase i study of oral panobinostat (LBH589) in Japanese patients with advanced solid tumors","volume":"30","author":"Fukutomi","year":"2012","journal-title":"Invest. New Drugs"},{"key":"10.1016\/j.lungcan.2023.01.003_b0145","doi-asserted-by":"crossref","unstructured":"G.R. Giaccone, A.;Ruijter, R.;Smit, E.;Van Groeningen, C.;Hogendoorn, P. C. W., Imatinib mesylate in patients with WHO B3 thymomas and thymic carcinomas, J. Thorac. Oncol. 4(10) (2009) 1270-1273doi: 10.1097\/JTO.0b013e3181b6be57.","DOI":"10.1097\/JTO.0b013e3181b6be57"},{"key":"10.1016\/j.lungcan.2023.01.003_b0150","doi-asserted-by":"crossref","unstructured":"J.M.K. Brell, S. S.;Rath, L.;Bokar, J. A.;Savvides, P.;Gibbons, J.;Cooney, M. M.;Meropol, N. J.;Ivy, P.;Dowlati, A., Phase i trial of sunitinib and gemcitabine in patients with advanced solid tumors, Cancer Chemother. Pharmacol. 70(4) (2012) 547-553doi: 10.1007\/s00280-012-1936-5.","DOI":"10.1007\/s00280-012-1936-5"},{"key":"10.1016\/j.lungcan.2023.01.003_b0155","doi-asserted-by":"crossref","first-page":"78","DOI":"10.1016\/j.ejca.2019.03.012","article-title":"Single-arm, multicentre, phase II trial of nivolumab for unresectable or recurrent thymic carcinoma: PRIMER study","volume":"113","author":"Katsuya","year":"2019","journal-title":"Eur. J. Cancer"},{"key":"10.1016\/j.lungcan.2023.01.003_b0160","doi-asserted-by":"crossref","unstructured":"Y.G. Okuma, Y.;Ohyanagi, F.;Sunami, K.;Nakahara, Y.;Kitazono, S.;Kudo, K.;Tambo, Y.;Kanda, S.;Yanagitani, N.;Horiike, A.;Horinouchi, H.;Fujiwara, Y.;Nokihara, H.;Yamamoto, N.;Nishio, M.;Ohe, Y.;Hosomi, Y., Phase II trial of S-1 treatment as palliative-intent chemotherapy for previously treated advanced thymic carcinoma, Cancer Med. 9(20) (2020) 7418-7427doi: 10.1002\/cam4.3385.","DOI":"10.1002\/cam4.3385"},{"issue":"10","key":"10.1016\/j.lungcan.2023.01.003_b0165","doi-asserted-by":"crossref","first-page":"S346","DOI":"10.1016\/j.jtho.2018.08.297","article-title":"OA11.05 Phase II Study of Sunitinib in Patients with Thymic Carcinoma Previously Treated with Platinum-Based Chemotherapy (KOSMIC Trial)","volume":"13","author":"Kim","year":"2018","journal-title":"J. Thorac. Oncol."},{"key":"10.1016\/j.lungcan.2023.01.003_b0170","doi-asserted-by":"crossref","unstructured":"G.K. Giaccone, C.;Thompson, J.;McGuire, C.;Kallakury, B.;Chahine, J. J.;Manning, M.;Mogg, R.;Blumenschein, W. M.;Tan, M. T.;Subramaniam, D. S.;Liu, S. V.;Kaplan, I. M.;McCutcheon, J. N., Pembrolizumab in patients with thymic carcinoma: a single-arm, single-centre, phase 2 study, Lancet Oncol. 19(3) (2018) 347-355doi: https:\/\/dx.doi.org\/10.1016\/S1470-2045(18)30062-7.","DOI":"10.1016\/S1470-2045(18)30062-7"},{"key":"10.1016\/j.lungcan.2023.01.003_b0175","doi-asserted-by":"crossref","unstructured":"J.S. Sato, M.;Itoh, S.;Okuma, Y.;Niho, S.;Mizugaki, H.;Murakami, H.;Fujisaka, Y.;Kozuki, T.;Nakamura, K.;Nagasaka, Y.;Kawasaki, M.;Yamada, T.;Machida, R.;Kuchiba, A.;Ohe, Y.;Yamamoto, N., Lenvatinib in patients with advanced or metastatic thymic carcinoma (REMORA): a multicentre, phase 2 trial, Lancet Oncol. 21(6) (2020) 843-850doi: 10.1016\/S1470-2045%2820%2930162-5.","DOI":"10.1016\/S1470-2045(20)30162-5"},{"issue":"15_suppl","key":"10.1016\/j.lungcan.2023.01.003_b0180","doi-asserted-by":"crossref","first-page":"e20578","DOI":"10.1200\/JCO.2018.36.15_suppl.e20578","article-title":"A phase 1b study of napabucasin (NAPA) + weekly paclitaxel (PTX) in patients (pts) with advanced thymoma and thymic carcinoma","volume":"36","author":"Kalra","year":"2018","journal-title":"J. Clin. Oncol."},{"issue":"24","key":"10.1016\/j.lungcan.2023.01.003_b0185","doi-asserted-by":"crossref","first-page":"2162","DOI":"10.1200\/JCO.2017.77.3184","article-title":"Pembrolizumab for patients with refractory or relapsed thymic epithelial tumor: an open-label phase II trial","volume":"37","author":"Cho","year":"2018","journal-title":"J. Clin. Oncol."},{"issue":"12","key":"10.1016\/j.lungcan.2023.01.003_b0190","doi-asserted-by":"crossref","first-page":"1940","DOI":"10.1016\/j.jtho.2018.07.094","article-title":"A Phase II Study of Pemetrexed in Patients with Recurrent Thymoma and Thymic Carcinoma","volume":"13","author":"Gbolahan","year":"2018","journal-title":"J. Thorac. Oncol."},{"issue":"12","key":"10.1016\/j.lungcan.2023.01.003_b0195","doi-asserted-by":"crossref","first-page":"1805","DOI":"10.1097\/JTO.0000000000000362","article-title":"Phase II study of amrubicin combined with carboplatin for thymic carcinoma and invasive thymoma north Japan lung cancer group study 0803","volume":"9","author":"Inoue","year":"2014","journal-title":"J. Thorac. Oncol."},{"issue":"2","key":"10.1016\/j.lungcan.2023.01.003_b0200","doi-asserted-by":"crossref","first-page":"191","DOI":"10.1016\/S1470-2045(13)70596-5","article-title":"Cixutumumab for patients with recurrent or refractory advanced thymic epithelial tumours: A multicentre, open-label, phase 2 trial","volume":"15","author":"Rajan","year":"2014","journal-title":"Lancet Oncol."},{"issue":"15_suppl","key":"10.1016\/j.lungcan.2023.01.003_b0205","doi-asserted-by":"crossref","first-page":"8579","DOI":"10.1200\/JCO.2018.36.15_suppl.8579","article-title":"A phase II study of regorafenib in patients with thymic epithelial tumours previously treated with chemotherapy","volume":"36","author":"Perrino","year":"2018","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.lungcan.2023.01.003_b0210","doi-asserted-by":"crossref","unstructured":"G.B. Palmieri, C.;Ottaviano, M.;Federico, P.;Calabrese, F.;Von Arx, C.;De Maio, A. P.;Marino, M.;Lalle, M.;Montella, L.;Merola, C.;Milella, M.;Bergaglio, M.;Di Lorenzo, G.;Damiano, V., Capecitabine plus gemcitabine in thymic epithelial tumors: final analysis of a Phase II trial, Fut. Oncol. 10(14) (2014) 2141-7doi: https:\/\/dx.doi.org\/10.2217\/fon.14.144.","DOI":"10.2217\/fon.14.144"},{"issue":"4","key":"10.1016\/j.lungcan.2023.01.003_b0215","doi-asserted-by":"crossref","first-page":"342","DOI":"10.1200\/JCO.2017.74.4078","article-title":"Phase II Study of Everolimus in Patients With Thymoma and Thymic Carcinoma Previously Treated With Cisplatin-Based Chemotherapy","volume":"36","author":"Zucali","year":"2018","journal-title":"J. Clin. Oncol."},{"issue":"15","key":"10.1016\/j.lungcan.2023.01.003_b0220","doi-asserted-by":"crossref","first-page":"2052","DOI":"10.1200\/JCO.2010.32.4467","article-title":"Phase II study of belinostat in patients with recurrent or refractory advanced thymic epithelial tumors","volume":"29","author":"Giaccone","year":"2011","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.lungcan.2023.01.003_b0225","doi-asserted-by":"crossref","unstructured":"Y.I. Tsukita, A.;Sugawara, S.;Kuyama, S.;Nakagawa, T.;Harada, D.;Tanaka, H.;Watanabe, K.;Mori, Y.;Harada, T.;Hino, T.;Fujii, M.;Ichinose, M., Phase II study of S-1 in patients with previously-treated invasive thymoma and thymic carcinoma: North Japan lung cancer study group trial 1203, Lung cancer (Amsterdam, Netherlands) 139 (2020) 89-93doi: 10.1016\/j.lungcan.2019.10.016.","DOI":"10.1016\/j.lungcan.2019.10.016"},{"issue":"10","key":"10.1016\/j.lungcan.2023.01.003_b0230","doi-asserted-by":"crossref","first-page":"1210","DOI":"10.1634\/theoncologist.2017-0586","article-title":"Prognostic Factors and Efficacy of First-Line Chemotherapy in Patients with Advanced Thymic Carcinoma: A Retrospective Analysis of 286 Patients from NEJ023 Study","volume":"23","author":"Ko","year":"2018","journal-title":"Oncologist"},{"key":"10.1016\/j.lungcan.2023.01.003_b0235","doi-asserted-by":"crossref","first-page":"122","DOI":"10.1016\/j.lungcan.2020.08.014","article-title":"Prognostic factors for patients with metastatic or recurrent thymic carcinoma receiving palliative-intent chemotherapy","volume":"148","author":"Okuma","year":"2020","journal-title":"Lung Cancer (Amsterdam, Netherlands)"},{"issue":"1","key":"10.1016\/j.lungcan.2023.01.003_b0240","doi-asserted-by":"crossref","first-page":"75","DOI":"10.1016\/j.lungcan.2012.12.012","article-title":"Clinical outcomes with chemotherapy for advanced thymic carcinoma","volume":"80","author":"Okuma","year":"2013","journal-title":"Lung Cancer (Amsterdam, Netherlands)"},{"issue":"28","key":"10.1016\/j.lungcan.2023.01.003_b0245","doi-asserted-by":"crossref","first-page":"e324","DOI":"10.1097\/MD.0000000000000324","article-title":"Long-term follow-up and prognostic factors for advanced thymic carcinoma","volume":"93","author":"Wu","year":"2014","journal-title":"Medicine (Baltimore)"},{"issue":"2","key":"10.1016\/j.lungcan.2023.01.003_b0250","doi-asserted-by":"crossref","first-page":"177","DOI":"10.1016\/S1470-2045(14)71181-7","article-title":"Sunitinib in patients with chemotherapy-refractory thymoma and thymic carcinoma: An open-label phase 2 trial","volume":"16","author":"Thomas","year":"2015","journal-title":"Lancet Oncol."},{"issue":"1","key":"10.1016\/j.lungcan.2023.01.003_b0255","doi-asserted-by":"crossref","first-page":"19","DOI":"10.1093\/annonc\/mdp478","article-title":"Influence of an independent review committee on assessment of response rate and progression-free survival in phase III clinical trials","volume":"21","author":"Tang","year":"2010","journal-title":"Ann. Oncol."},{"issue":"2","key":"10.1016\/j.lungcan.2023.01.003_b0260","doi-asserted-by":"crossref","first-page":"268","DOI":"10.1016\/j.ejca.2008.10.031","article-title":"Lessons learned from independent central review","volume":"45","author":"Ford","year":"2009","journal-title":"Eur. J. Cancer"},{"issue":"3","key":"10.1016\/j.lungcan.2023.01.003_b0265","doi-asserted-by":"crossref","first-page":"500","DOI":"10.1097\/JTO.0000000000000429","article-title":"Diffuse high intensity PD\u2013L1 staining in thymic epithelial tumors","volume":"10","author":"Padda","year":"2015","journal-title":"J. Thorac. Oncol."},{"issue":"6","key":"10.1016\/j.lungcan.2023.01.003_b0270","doi-asserted-by":"crossref","first-page":"826","DOI":"10.1038\/modpathol.2017.6","article-title":"Expression of PD-1 and PD-L1 in thymic epithelial neoplasms","volume":"30","author":"Weissferdt","year":"2017","journal-title":"Mod. Pathol."},{"issue":"8","key":"10.1016\/j.lungcan.2023.01.003_b0275","doi-asserted-by":"crossref","first-page":"e0182665","DOI":"10.1371\/journal.pone.0182665","article-title":"Expression of PD-L1 and other immunotherapeutic targets in thymic epithelial tumors","volume":"12","author":"Arbour","year":"2017","journal-title":"PLoS One"},{"key":"10.1016\/j.lungcan.2023.01.003_b0280","article-title":"Abstract A92: effects of lenvatinib on tumor-associated macrophages enhance antitumor activity of PD-1 signal inhibitors","author":"Kato","year":"2015","journal-title":"AACR"},{"issue":"suppl_6","key":"10.1016\/j.lungcan.2023.01.003_b0285","article-title":"Lenvatinib mesilate (LEN) enhanced antitumor activity of a PD-1 blockade agent by potentiating Th1 immune response","volume":"27","author":"Kato","year":"2016","journal-title":"Ann. Oncol."},{"issue":"12","key":"10.1016\/j.lungcan.2023.01.003_b0290","doi-asserted-by":"crossref","first-page":"3993","DOI":"10.1111\/cas.13806","article-title":"Immunomodulatory activity of lenvatinib contributes to antitumor activity in the Hepa1-6 hepatocellular carcinoma model","volume":"109","author":"Kimura","year":"2018","journal-title":"Cancer Sci."},{"issue":"26","key":"10.1016\/j.lungcan.2023.01.003_b0295","doi-asserted-by":"crossref","first-page":"2981","DOI":"10.1200\/JCO.19.02627","article-title":"Lenvatinib plus pembrolizumab in patients with advanced endometrial cancer","volume":"38","author":"Makker","year":"2020","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.lungcan.2023.01.003_b0300","unstructured":"U. Food, D. Administration, FDA approves lenvatinib plus pembrolizumab for advanced renal cell carcinoma, 2021."},{"key":"10.1016\/j.lungcan.2023.01.003_b0305","unstructured":"U. Food, D. Administration, FDA Grants Regular Approval to Pembrolizumab and Lenvatinib for Advanced Endometrial Carcinoma, 2021."},{"key":"10.1016\/j.lungcan.2023.01.003_b0310","unstructured":"J.B. Remon, Benjamin, Combination of Pembrolizumab and Lenvatinib, in Pre-treated Thymic CArcinoma paTIents (PECATI), 2021. https:\/\/clinicaltrials.gov\/ct2\/show\/NCT04710628. (Accessed November 22 2021)."},{"key":"10.1016\/j.lungcan.2023.01.003_b0315","doi-asserted-by":"crossref","unstructured":"K.H.H. Kim, J. Y.;Cho, J.;Ku, B. M.;Koh, J.;Koh, J. Y.;Sun, J. M.;Lee, S. H.;Ahn, J. S.;Park, K.;Ahn, M. J.;Shin, E. C., Immune-related adverse events are clustered into distinct subtypes by T-cell profiling before and early after anti-PD-1 treatment, OncoImmunology 9 (1) (no pagination)(1722023) (2020) doi: 10.1080\/2162402X.2020.1722023.","DOI":"10.1080\/2162402X.2020.1722023"},{"key":"10.1016\/j.lungcan.2023.01.003_b0320","doi-asserted-by":"crossref","unstructured":"G.C. Giaccone, J.;Kim, C.;Ahn, M. J., Follow-up Update of 2 Phase Ii Studies of Pembrolizumab in Thymic Carcinoma, World Conference on Lung Cancer 2019, 2019.","DOI":"10.1016\/j.jtho.2019.08.667"},{"issue":"3","key":"10.1016\/j.lungcan.2023.01.003_b0325","doi-asserted-by":"crossref","first-page":"483","DOI":"10.1016\/j.jtho.2020.11.003","article-title":"Durable Response in Patients With Thymic Carcinoma Treated With Pembrolizumab After Prolonged Follow-Up","volume":"16","author":"Giaccone","year":"2021","journal-title":"J. Thorac. Oncol."},{"issue":"10","key":"10.1016\/j.lungcan.2023.01.003_b0330","doi-asserted-by":"crossref","first-page":"S331","DOI":"10.1016\/j.jtho.2019.08.667","article-title":"05 Follow-Up Update of 2 Phase II Studies of Pembrolizumab in Thymic Carcinoma","volume":"14","author":"Giaccone","year":"2019","journal-title":"J. Thorac. Oncol."},{"issue":"6","key":"10.1016\/j.lungcan.2023.01.003_b0335","doi-asserted-by":"crossref","first-page":"1168","DOI":"10.1093\/annonc\/mdp483","article-title":"Preliminary results of phase II study of capecitabine and gemcitabine (CAP-GEM) in patients with metastatic pretreated thymic epithelial tumors (TETs)","volume":"21","author":"Palmieri","year":"2010","journal-title":"Ann. Oncol."},{"key":"10.1016\/j.lungcan.2023.01.003_b0340","doi-asserted-by":"crossref","unstructured":"S.S. Itoh, M.;Sato, J.;Okuma, Y.;Niho, S.;Mizugaki, H.;Murakami, H.;Fujisaka, Y.;Kozuki, T.;Nakamura, K.;Nagasaka, Y.;Kawasaki, M.;Yamada, T.;Kuchiba, A.;Yamamoto, N., Durable Anti-Tumor Activity of the Multi-Targeted Inhibitor Lenvatinib In Patients With Advanced Or Metastatic Thymic Carcinoma: Preliminary Results From a Multicenter Phase II (REMORA) Trial, European Society for Medical Oncology Congress 2019, 2019.","DOI":"10.1093\/annonc\/mdz266.003"}],"container-title":["Lung Cancer"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S016950022300003X?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S016950022300003X?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,9,30]],"date-time":"2025-09-30T13:04:23Z","timestamp":1759237463000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S016950022300003X"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,2]]},"references-count":68,"alternative-id":["S016950022300003X"],"URL":"https:\/\/doi.org\/10.1016\/j.lungcan.2023.01.003","relation":{},"ISSN":["0169-5002"],"issn-type":[{"value":"0169-5002","type":"print"}],"subject":[],"published":{"date-parts":[[2023,2]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Efficacy and safety of treatments for advanced thymic carcinoma after failure of first-line platinum-based chemotherapy: A systematic literature review and meta-analysis","name":"articletitle","label":"Article Title"},{"value":"Lung Cancer","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.lungcan.2023.01.003","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2023 The Authors. Published by Elsevier B.V.","name":"copyright","label":"Copyright"}]}}